MedTrace Logo

Montelukast in Modulating Exacerbations of Asthma in Children

NCT00196547 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2012-03-16

No results posted yet for this study

Summary

The purpose of the study is to determine if Montelukast added to other therapy, if any, will reduce the severity of asthma symptoms in children during the high incidence of respiratory viral infections that occur in children in the post Labor Day school return period.

Conditions

Interventions

DRUG

Montelukast (drug)

Sponsors & Collaborators

  • Firestone Institute for Respiratory Health

    lead OTHER

Principal Investigators

  • Malcolm R Sears, MB. ChB · Firestone Institute for Respiratory Health, St. Joseph's Healthcare, Hamilton

  • Neil W Johnston, MSc · Firestone Institute for Respiratory Health, St. Joseph's Healthcare, Hamilton

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SINGLE_GROUP

Eligibility

Min Age
2 Years
Max Age
14 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-09-30
Completion
2005-11-30

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00196547 on ClinicalTrials.gov